This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Trandolapril

September 9, 2025

Therapeutic category

Antihypertensives

Non-proprietary name

Trandolapril

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current	Revision
11. ADVERSE REACTIONS	11. ADVERSE REACTIONS
11.1 Clinically Significant Adverse Reactions	11.1 Clinically Significant Adverse Reactions
Angioedema	Angioedema
Angioedema accompanied by dyspnoea, with swelling of the face,	Angioedema accompanied by dyspnoea, with swelling of the face,
tongue, glottis, and larynx, may occur. If any abnormalities are	tongue, glottis, and larynx, may occur. If any abnormalities are
observed, administration should be discontinued immediately, and	observed, administration should be discontinued immediately, and
appropriate measures should be taken, such as administering	appropriate measures should be taken, such as administering
adrenaline injections and maintaining the airway. Occurrences of	adrenaline injections and maintaining the airway. Of note, intestinal
intestinal angioedema (symptoms: Abdominal pain, queasy,	angioedema accompanied by abdominal pain, queasy, vomiting,
vomiting, diarrhoea, etc.) have been reported with other angiotensin-	diarrhoea, etc. may occur.
converting enzyme inhibitors.	